Commercialization Pinova, a welfare technology start-up

Our innovation addresses the societal challenge and market opportunity the ageing of the European population represents.

Our innovation makes it possible to continue live safely at home for an extended period, despite age-related functional and mental impairment (UN Sustainable Development Goal #3).Using a non-intrusive system of sensors, algorithms, and artificial intelligence we identify incidents in elderly’s homes.

With activity out-of-the-ordinary their loved ones automatically get alerted by a digital generated phone call, explaining the incident. Our innovation is user friendly; no alarm button, application or video surveillance is necessary. We want to penetrate the consumer marked with affordable welfare technology solutions.

We are disrupting the industry with deep tech innovations and by using easily accessible sensor technology in a rapid growing market. The current stage of our innovation is testing the beta-version in private homes. After the test period the greatest challenge for our startup and innovation is commercialization and market growth.

By participating in The Woman Tech EU program, we aim at bringing our startup closer to commercialization, making proof of concept, product-marked-fit and go-to-market-strategy. The program will be a valued partner pursuing our goals. We believe that mentors from the program will be an important contribution in knowhow of business development.

The opportunity to build an international network of experienced mentors and founders will both be inspirational and important.

This program will also give us the opportunity to speed up activities.I’m an experienceI’m an experienced top-level manager, especially within organizational development, operations, and corporate finance, all at a national business level.

Consequently, coaching and mentoring in marketing, growth strategy, and business development into international market would be of utmost value to me personally, and of great importance for Pinova.